Lu et al. discovered that CSMD3 is linked to tumor mutation burden and immune infiltration in ovarian cancer patients [21] and was identified as a potential driver gene in prostate adenocarcinoma. This evidence concerns the gene CSMD3 and ovarian carcinoma.